

## Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico

Omar Yaxmehen Bello-Chavolla,<sup>1,2</sup> Jessica Paola Bahena-López,<sup>3</sup> Neftali Eduardo Antonio-Villa,<sup>1,3</sup> Arsenio Vargas-Vázquez,<sup>1,3</sup> Armando González-Díaz,<sup>4</sup> Alejandro Márquez-Salinas,<sup>2,3</sup> Carlos A. Fermín-Martínez,<sup>1,3</sup> J. Jesús Naveja,<sup>5</sup> and Carlos A. Aguilar-Salinas<sup>1,6,7</sup>

<sup>1</sup>Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; <sup>2</sup>Division of Research, Instituto Nacional de Geriátria, Mexico City, Mexico; <sup>3</sup>Plan de Estudios Comcinados en Medicina (PECEM), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico; <sup>4</sup>Centro de Estudios en Antropología, Facultad de Ciencias Políticas y Sociales, Universidad Nacional Autónoma de México, Mexico City, Mexico; <sup>5</sup>Department of Physicochemistry, Instituto de Química, Universidad Nacional Autónoma de México, Mexico City, Mexico; <sup>6</sup>Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; and <sup>7</sup>Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico

**ORCID numbers:** 0000-0003-3093-937X (O. Y. Bello-Chavolla); 0000-0001-8419-687X (J. P. Bahena-López); 0000-0002-6879-1078 (N. E. Antonio-Villa); 0000-0002-0051-7689 (A. Vargas-Vázquez); 0000-0001-8640-6690 (J. J. Naveja); 0000-0001-8517-0241 (C. A. Aguilar-Salinas).

**Background:** The SARS-CoV-2 outbreak poses a challenge to health care systems due to its high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity, and its role in improving risk prediction.

**Methods:** We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of the Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19-related lethality. Finally, we built a clinical score to predict COVID-19 lethality.

**Results:** Among the 177 133 subjects at the time of writing this report (May 18, 2020), we observed 51 633 subjects with SARS-CoV-2 and 5,332 deaths. Risk factors for lethality in COVID-19 include early-onset diabetes, obesity, chronic obstructive pulmonary disease, advanced age, hypertension, immunosuppression, and chronic kidney disease (CKD); we observed that obesity mediates 49.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for intensive care unit admission and intubation. Our predictive score for COVID-19 lethality included age  $\geq$  65 years, diabetes, early-onset diabetes, obesity, age  $<$  40 years, CKD, hypertension, and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (C-statistic = 0.823).

**Conclusions:** Here, we propose a mechanistic approach to evaluate the risk for complications and lethality attributable to COVID-19, considering the effect of obesity and diabetes in Mexico.

Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first-contact scenario. (*J Clin Endocrinol Metab* 105: 2752–2761, 2020)

**Freeform/Key Words:** COVID-19, SARS-CoV-2, diabetes, obesity, lethality, Mexico

The first cases of SARS-CoV-2 infection in Mexico were reported at the end of February (1); since then, the number of COVID-19 cases has been steadily increasing, with most fatal cases being associated with the presence of comorbidity and, particularly, cardiometabolic comorbidities. A high prevalence of cardiometabolic diseases worldwide represents a challenge during the COVID-19 epidemic; an elevated number of patients with SARS-CoV-2 infection have a preexisting disease, such as obesity, hypertension, cardiovascular disease, diabetes, chronic respiratory disease, or cancer (2, 3). Diabetes mellitus and obesity represent a large share of the cardiometabolic morbidity burden of the region (4); moreover, most cases of diabetes remain either undiagnosed or lack adequate glycemic control, which puts these cases at a risk of increased COVID-19 severity. Despite several reports evaluating the burden of comorbidities (including obesity, diabetes, and hypertension) on the clinical course of COVID-19, the joint role of obesity and diabetes in modifying COVID-19 outcomes has not been fully explored (5).

Several studies have demonstrated a higher susceptibility to acute respiratory infectious diseases in people with diabetes (6). Moreover, diabetes and obesity have been described as independent risk factors for severe pulmonary infection (7, 8). Obesity influences the clinical outcomes during acute severe respiratory distress syndrome; for example, obesity has been proposed as a protective factor for mortality following lung injury due to reverse causality but also as a cause of mortality and adverse clinical outcomes for severe influenza cases due to mechanical and immunologic factors. In the cases of the COVID-19 outbreak, obesity has been consistently associated with adverse outcomes (9, 10). Furthermore, a large proportion of obesity cases in Mexico live in geographical areas of increased social vulnerability, which poses a structural inequality that might also increase mortality for COVID-19 associated to both diabetes and obesity (11). Chronic inflammation in obesity might worsen the acute inflammatory response triggered by a SARS-CoV-2 infection, which might be associated to a cytokine release syndrome (5, 12). Here, we investigate the role of both diabetes and obesity in determining the propensity for a SARS-CoV-2 infection and its associated clinical outcomes, including disease severity and COVID-19 lethality; using these associations, we further construct a clinically useful predictive model

for COVID-19 mortality using national epidemiological surveillance data from Mexico.

## Methods

### Data sources

We extracted data from the General Directorate of Epidemiology of the Mexican Ministry of Health, which is an open-source dataset comprising daily updated information of suspected COVID-19 cases, which have been confirmed with a positive test for SARS-CoV-2 certified by the National Institute for Diagnosis and Epidemiological Referral (13).

### Definitions of suspected and confirmed COVID-19 cases

The Ministry of Health defines a suspected COVID-19 case as an individual of any age whom in the last 7 days has presented with at least 2 of the following: cough, fever, or headache, accompanied by either dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis, or chest pain. Amongst these suspected cases, the Ministry of Health establishes 2 protocols for case confirmation: (1) widespread SARS-CoV-2 testing is done for suspected COVID-19 cases with severe acute respiratory infection and with signs of breathing difficulty or deaths, and (2) for all other suspected cases, a sentinel surveillance model is being utilized, whereby 475 nationally represented health facilities sample ~10% of mild outpatient cases and all suspected severe acute respiratory infections (14). Demographic and health data are collected and uploaded to the epidemiologic surveillance database by personnel from the corresponding individual facility.

### Variables and definitions

Available information for all confirmed, negative, and suspected COVID-19 cases includes age, sex, nationality, state, municipality where the case was detected, immigration status, as well as identification of individuals who speak indigenous languages. Health information includes status of diabetes, obesity, chronic obstructive pulmonary disease (COPD), immunosuppression, pregnancy, arterial hypertension, cardiovascular disease, chronic kidney disease (CKD), and asthma. Date of symptom onset, hospital admission, and death are available for all cases as well as treatment status (outpatient or hospitalized), information regarding diagnosis of pneumonia, intensive care unit (ICU) admission and whether the patient required invasive mechanical ventilation. Early-onset diabetes was defined as a medically diagnosed case of diabetes mellitus in subjects younger than 40 years of age. The majority of early-onset diabetes cases are patients with type 2 diabetes. This phenotype is common in Mexico; it is characterized by having a more aggressive form of the disease that is usually associated with obesity, rapidly declining  $\beta$ -cell function, and higher risk of microvascular complications compared to late-onset type 2 diabetes (15). We considered this

form of diabetes given its high prevalence in Mexican and other populations as well as its higher propensity for complications (16, 17).

## Statistical analysis

**Comorbidities associated to SARS-CoV-2 positivity.** We investigated the association of demographic and health data associated with SARS-CoV-2 positivity using logistic regression analyses, excluding individuals who were only suspected but unconfirmed cases of COVID-19. Next, we stratified these analyses for individuals with only diabetes or only obesity to identify specific risk factors within these populations, especially focusing on individuals who were < 40 years old and likely acquired the disease early.

**COVID-19 mortality risk.** In order to investigate risk factors predictive of COVID-19-related 30-day lethality, we fitted Cox proportional risk regression models estimating time from symptom onset up to death or censoring, whichever occurred first in cases with confirmed positivity for SARS-CoV-2. To identify diabetes and obesity-specific risk factors, we carried out stratified analyses. Given the availability of SARS-CoV-2 negative cases within the dataset, we fitted Cox models for mortality, which included SARS-CoV-2 positivity as an interaction term with different comorbidities, hypothesizing that some factors increase mortality risk specifically for COVID-19. Finally, we fitted a logistic regression model only for mortality cases to evaluate associations with lethality rates in COVID-19-related and nonrelated deaths.

**Influence of obesity and diabetes in COVID-19 related outcomes.** Finally, we estimated factors associated to the admission to hospital facilities, ICUs, and requirements for mechanical ventilation in all confirmed COVID-19 cases using logistic regression. To identify specific factors for all COVID-19 and non-COVID-19 patients related to outcomes, we included interaction effects with comorbidity factors; we also performed Kaplan-Meier analyses to identify the role of comorbidities in modifying lethality risk in individuals with diabetes and obesity, and we compared across the categories using Breslow-Cox tests. Finally, we performed causal-mediation analyses with causally ordered mediators using a previously validated approach to investigate whether obesity mediates the decrease in COVID-19 survival that is attributable to diabetes, particularly in early-onset cases of < 40 years of age (18).

**Mechanistic mortality risk score for COVID-19.** Finally, we constructed a clinically useful model to predict lethality in COVID-19 cases, which might be useful to apply in first contact settings, including variables and interactions, which were identified in mortality analyses. The model was trained in 80% of the dataset and split using random sampling stratified by mortality status with the *caret* R package and was later validated in the remaining 20%. Points were assigned by standardizing all  $\beta$  coefficients with the minimum absolute  $\beta$  coefficient obtained from Cox regression models. Points were stratified according to categories of low risk ( $\leq 0$ ), mild risk (1–3), moderate risk (4–6), high risk (7–9), and very high risk ( $\geq 10$ ). Risk across categories was verified using Kaplan-Meier analyses. C-statistics and  $D_{xy}$  values were corrected for

overoptimism using k-fold cross-validation ( $k = 10$ ) using the *rms* R package. A  $P$ -value < 0.05 was considered the statistical significance threshold. All analyses were performed using R software version 3.6.2.

## Results

### COVID-19 cases in Mexico

At the time of writing this report (May 18, 2020), a total of 177 133 subjects had been treated initially as suspected COVID-19 cases. Amongst them, 51 633 were confirmed as positive and 98 567 tested negative for SARS-CoV-2 infection; additionally, 26 933 cases were still being studied as suspected cases pending testing results. Amongst the confirmed cases, 5332 deaths were reported (10.33%), with 2009 deaths reported as SARS-CoV-2 negative cases (2.04%) and 656 deaths suspected but unconfirmed cases (2.44%). Compared to SARS-CoV-2 negative cases, the confirmed cases were older, predominantly male (1.37:1 ratio), had higher rates of hospitalization, and showed a higher prevalence of diabetes, hypertension, and obesity. The SARS-CoV-2 cases were also more likely have higher rates of ICU admission and requirements for invasive ventilation compared to negative cases (Table 1).

### Factors associated with COVID-19 positivity

We investigated cases related to COVID-19 positivity within Mexico. We found that the odds of SARS-CoV-2 positivity was higher with diabetes, hypertension, obesity, age > 65 years, and male sex. When assessing age, we observed reduced odds of SARS-CoV-2 positivity in patients < 40 years and, in contrast, when exploring its interaction with diabetes, we observed an increased probability of SARS-CoV-2 infection. In stratified models, we observed that for patients with diabetes, SARS-CoV-2 positivity was associated with obesity, diabetes, and male sex, as was the interaction between diabetes and an age < 40 years (19).


### Predictors for COVID-19-related 30-day mortality

We identified that COVID-19 cases were associated with a near 4-fold increase in mortality due to acute respiratory infection (Hazard Ratio [HR] 3.967; 95% confidence interval [CI], 3.739–4.210) compared to non-COVID-19 cases. Of interest, the only comorbidity that conferred an increased risk of death exclusively for COVID-19 compared to non-COVID-19 was obesity (HR 1.261; 95% CI, 1.109–1.433) (Fig. 1A). Factors associated to increased risk of death in COVID-19 cases were age > 65 years, diabetes mellitus, obesity, CKD, COPD, immunosuppression, and hypertension, while asthma showed a protective effect (Fig. 1B). We searched for an

**Table 1. Descriptive statistics comparing negative, positive, and suspected cases for SARS-CoV-2 in Mexico**

Parameter	Positive for SARS-CoV-2 n = 51 633	Negative for SARS-CoV-2 n = 98 567	Suspected for SARS-CoV-2 n = 26 933
Age (mean ± sd)	46.65 ± 15.83	40.25 ± 17.33	43.3 ± 16.55
Male sex (%)	29 803 (57.7)	47 177 (47.9)	13 602 (50.5)
Mortality (%)	5332 (10.3)	2009 (2.0)	656 (2.4)
Hospitalization (%)	19 831 (38.4)	18 586 (18.9)	6674 (24.8)
Pneumonia (%)	14 919 (28.9)	11 928 (12.1)	4723 (17.5)
ICU admission (%)	1893 (3.7)	1456 (1.5)	464 (1.7)
Invasive ventilation (%)	1959 (3.8)	1162 (1.2)	406 (1.5)
Diabetes (%)	9460 (18.3)	10 553 (10.7)	3442 (12.8)
COPD (%)	1131 (2.2)	2238 (2.3)	444 (1.6)
Asthma (%)	1602 (3.1)	4530 (4.6)	725 (2.7)
Immunosuppression (%)	849 (1.6)	2472 (2.5)	393 (1.5)
Hypertension (%)	11 151 (21.6)	14 858 (15.1)	4453 (16.5)
Obesity (%)	10 708 (20.7)	14 011 (14.2)	4364 (16.2)
CKD (%)	1265 (2.4)	2270 (2.3)	525 (1.9)
CVD (%)	1381 (2.7)	2891 (2.9)	595 (2.2)
Smoking (%)	4366 (8.5)	9624 (9.8)	2451 (9.1)

Abbreviations: COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CVD, cardiovascular disease; ICU, intensive care unit.



**Figure 1.** Cox proportional risk regression analysis to evaluate the lethality of SARS-CoV-2 in Mexico, compared to SARS-CoV2 negative cases for all suspected cases with SARS-CoV2 status available (**A**) and stratified by diabetes mellitus (**B**) and obesity (**C**). Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HR, hazard ratio; ICU, intensive care unit; vs 7.7%), hospitalization, ICU admission, requirement for invasive ventilation, and confirmed pneumonia compared with those without diabetes. When stratifying mortality, those with early-onset diabetes (< 40 years of age) had higher mortality rates compared to individuals < 40 years of age without diabetes (11.3% vs 1.3%); similarly, those aged > 40 years without diabetes had lower mortality rates compared to those > 40 years with diabetes (12.0% vs 22.7%). As expected, obesity, hypertension, COPD, CKD, Cardiovascular Disease (CVD), and immunosuppression were also more prevalent in this population (19). In patients with diabetes mellitus, COVID-19-related mortality was higher in those with concomitant immunosuppression, COPD, CKD, hypertension, and those aged > 65 years

interaction between diabetes mellitus and age < 40 years to account for early-onset diabetes mellitus, adjusted for sex and obesity; a higher mortality risk was found for early-onset diabetes cases (HR 2.754; 95% CI, 2.259–3.359). Adjusting the model for pneumonia to account for SARS-CoV-2 severity as a predictor of mortality (HR 5.264; 95% CI, 4.933–5.618), we observed that asthma was no longer associated to decreased mortality, whilst all other predictors remained constant.

### COVID-19 in patients with diabetes mellitus

Confirmed COVID-19 cases with diabetes had a mean age of 57.16 (±12.83) years and were predominantly male. This population had particularly higher mortality rate (21.8%

vs 7.7%), hospitalization, ICU admission, requirement for invasive ventilation, and confirmed pneumonia compared with those without diabetes. When stratifying mortality, those with early-onset diabetes (< 40 years of age) had higher mortality rates compared to individuals < 40 years of age without diabetes (11.3% vs 1.3%); similarly, those aged > 40 years without diabetes had lower mortality rates compared to those > 40 years with diabetes (12.0% vs 22.7%). As expected, obesity, hypertension, COPD, CKD, Cardiovascular Disease (CVD), and immunosuppression were also more prevalent in this population (19). In patients with diabetes mellitus, COVID-19-related mortality was higher in those with concomitant immunosuppression, COPD, CKD, hypertension, and those aged > 65 years



(Fig. 1C). When assessing the role of comorbidities, COVID-19 patients with diabetes, obesity, early-onset diabetes (< 40 years), or an increase in the number of comorbidities had increased risk of COVID-19 lethality (Breslow test  $P < 0.001$ ) (Fig. 2). When comparing cases with and without COVID-19 among patients with diabetes mellitus, we observed a 3-fold higher risk of mortality associated with COVID-19 (HR 3.375; 95% CI, 3.103–3.672) after adjusting for age, sex, and comorbidities (19).

**COVID-19 in patients with obesity**

Similar to patients with diabetes, confirmed COVID-19 cases with obesity had particularly higher rates of mortality (Comparing patients with and without obesity, 13.5% vs 9.4%), hospitalization, and confirmed pneumonia. Furthermore, patients with obesity also had higher rates of ICU admission (Comparing patients with and without obesity, 5.0% vs 3.3%) and were more likely to be intubated (Comparing patients with and without obesity, 5.2% vs 3.3%). As expected, diabetes, hypertension, COPD, smoking, CVD, and asthma were also more prevalent in patients with obesity (19). As previously mentioned, obesity was identified as a risk factor, which displayed differential risk for COVID-19 infection, and specific risk factors for lethality in obese patients with COVID-19 included COPD, CKD, hypertension, male sex, age > 65, diabetes, and, particularly, early-onset type 2 diabetes (Fig. 1D); overall, COVID-19 increased the risk


of mortality in obesity nearly 5-fold (HR 4.989; 95% CI, 4.444–5.600). The addition of obesity to any number of comorbidities significantly increased the risk for COVID-19 lethality (Breslow test  $P < 0.001$ ) (Fig. 2C). Using causally ordered mediation analysis we investigated whether the effect of diabetes (E) on COVID-19-related lethality (Y) was partially mediated by obesity (M). The direct effect of diabetes on COVID-19 lethality was significant ( $\Delta_{E1 \rightarrow Y} = 1.45$ ; 95% CI, 1.36–1.54), as was the indirect effect of obesity ( $\Delta_{M1 \rightarrow Y} = 1.42$ ; 95% CI, 1.36–1.49), representing 49.5% of the total effect of diabetes.

**COVID-19 outcomes and comorbidities**


Given the increased risk of diabetes and obesity in modifying COVID-19-related lethality, a secondary objective of our study was to investigate its association with inpatient outcomes, including hospitalization rate, ICU admission, and requirement for mechanical ventilation. In general, early-onset diabetes patients and those with obesity had a higher risk of hospitalization, whilst patients with obesity also had an increased risk for ICU admission and required intubation. Patients with diabetes mellitus had an overall higher risk of hospitalization, risk of ICU admission, and intubation (Fig. 3).

**Mechanistic score for mortality in COVID-19**

Using the identified predictors for mortality and the observed interaction for early-onset diabetes, we



**Figure 2.** Kaplan-Meier survival curves to evaluate the lethality of SARS-CoV-2 positivity in patients with diabetes and comorbidities (A), diabetes and obesity (B), obesity and comorbidities (C), and diabetes with age <40 years (D). Abbreviations: Comorb, comorbidities; DM, diabetes mellitus; Ob, obesity.



**Figure 3.** Logistic regression analyses to evaluate COVID-19-related outcomes in all patients with SARS-CoV2 positivity for admission to ICU (A), mechanical ventilation (B), and hospital admission risk (C).

**Table 2.** Cox proportional risk models for lethality using the mechanistic COVID-19 lethality score in confirmed cases of COVID-19 using individual components, single score point, and risk stratification categories

Model	Parameter	B	Score	SE	Wald	HR	95% CI	P-Value
Individual variables <i>C-statistic</i> = 0.817	Age ≥ 65 years	0.705	3	0.034	20.868	2.02	1.89–2.16	<0.001
	Diabetes	0.294	1	0.034	8.668	1.34	1.26–1.43	<0.001
	Diabetes*Age < 40 years	1.052	5	0.138	7.618	2.86	2.19–3.76	<0.001
	Age < 40 years	-1.344	-6	0.070	-19.32	0.26	0.23–0.29	<0.001
	Obesity	0.225	1	0.035	6.376	1.25	1.17–1.34	<0.001
	Pneumonia	1.650	7	0.037	44.812	5.21	4.84–5.60	<0.001
	CKD	0.686	3	0.066	5.145	1.99	1.77–2.23	<0.001
	COPD	0.337	1	0.066	5.145	1.40	1.23–1.59	<0.001
	Immunosuppression	0.239	1	0.088	2.271	1.27	1.07–1.51	0.007
Score point training <i>C-statistic</i> = 0.823	1-Point increment	0.238		0.003	68.49	1.27	1.26–1.28	<0.001
Risk categories training <i>C-statistic</i> = 0.810	Low risk (≤0 pts)	Reference						
	Mild risk (1–3 pts)	1.794		0.071	25.40	6.01	5.24–6.91	<0.001
	Moderate risk (4–6 pts)	2.762		0.067	41.22	15.83	13.88–18.05	<0.001
	High risk (7–9 pts)	3.243		0.064	50.34	25.61	22.57–29.06	<0.001
	Very high risk (≥10 pts)	3.678		0.069	53.43	39.58	34.58–45.30	<0.001


Abbreviations: ; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.

designed a predictive score for COVID-19 mortality using Cox regression analysis, with a random split of 80% of the dataset stratified by mortality ( $n = 41\,307$ , deaths = 4,276). We identified the following: (1) age > 65 years, diabetes mellitus, obesity, CKD, COVID-19-related pneumonia, COPD, and immunosuppression as significant Predictors for mortality (Table 2); (2) age < 40 was a protective factor, which was modified by its interaction with type 2 diabetes ( $R^2=0.154$ ,  $C$ -statistic = 0.817,  $D_{xy}=0.647$ ); and (3) assigning the point system did not significantly reduce the model's performance ( $R^2=0.154$ ,  $C$ -statistic = 0.822,  $D_{xy}=0.645$ ). Finally, category stratification only moderately reduced performance statistics ( $R^2=0.152$ ,  $C$ -statistic = 0.810,  $D_{xy}=0.620$ ) and were not significantly modified after

cross-validation correction ( $R^2=0.167$ ,  $D_{xy}=0.645$ ). The score was then validated using the remaining 20% of the population ( $n = 10\,326$ , deaths = 1056); we observed that the score retained its predictive and discriminative ability ( $R^2=0.167$ ,  $C$ -statistic = 0.830,  $D_{xy} = 0.660$ ), as did the categories ( $R^2 = 0.170$ ,  $C$ -statistic = 0.821,  $D_{xy}=0.642$ ). Distribution of the score significantly discriminates between lethal and nonlethal COVID-19 cases (Fig. 4).

## Discussion

Our results demonstrate that diabetes (particularly early-onset diabetes), obesity, and comorbidity burden modify risk profiles in patients with COVID-19 in



**Figure 4.** Symptom onset among lethal and nonlethal cases in new-confirmed COVID-19 cases, stratified by diabetes and obesity status (A) and density histogram of scores of the mechanistic COVID-19 score (B). Points and score intervals considered for clinical score scale, where diabetes and age < 40 represent the score of the interaction term (C) and Kaplan-Meier survival analysis curves are used to evaluate lethality using risk categories in the training (D) and validation cohorts (E). Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; OB, obesity.

Mexico and significantly improve mortality prediction related to COVID-19 lethality. These findings position the notion that early-onset type 2 diabetes might carry a higher risk of mortality in younger patients, and the risk is similar in older patients with other comorbidities and only higher in older patients with diabetes. Inclusion of the interaction term (Diabetes\*Age < 40 years) within the risk score effectively offsets the protective effect of younger age, indicating that higher risk is attributable to early-onset diabetes and including this term within the risk score improves the prediction of mortality. Furthermore, our results suggest that obesity is a COVID-19-specific risk factor for mortality, ICU admission, tracheal intubation, and hospitalization, and it even increases risk in patients with comorbid diabetes and COVID-19 infection. Overall, this positions the coexistence of obesity and diabetes, particularly early-onset diabetes, as a considerable risk factor for COVID-19 mortality in Mexicans, whom have reported an alarmingly high burden of both conditions in recent health surveys.

The relationship between increased risk of mortality attributable to acute severe respiratory infections in patients with diabetes mellitus has been extensively

reported, particularly for the acute respiratory syndrome caused by SARS-CoV-1 (20–22). Evidence relating to SARS-CoV-2 infections in China demonstrated increased rates of diabetes mellitus in hospitalized patients and in those with increased disease severity, as assessed by ICU admission and the requirement for invasive ventilation. Additionally, hospitalized patients with COVID-19 had increased rates of both obesity and diabetes compared to nonhospitalized cases in the United States, China, and Italy (5, 23, 24). Increased susceptibility to COVID-19 in patients with diabetes may be explained by several reasons, including an increased lung Angiotensin-converting enzyme (ACE2) expression and elevated circulating levels of furin, a protease involved viral entry to cells, and a decreased clearance of SARS-CoV-2 viral particles in subjects with diabetes and/or hypertension associated with ACE2 expression (25–28). The impairments in immunity observed in patients with diabetes are characterized by an initial delay in activation of Th1 cell-mediated immunity and a late hyperinflammatory response, both of which are consistent with the increased risk for mortality associated with additional immunosuppression observed in our data (29). Additional factors, which have been

proposed to modify COVID-19 mortality risk and worsen glycemic control in diabetes, include corticosteroid therapy, inadequate glucose monitoring, the effect of social distancing on diabetes care, and the use of antihypertensive medication; however, these factors remain to be confirmed by clinical evidence (30). Given the large proportion of undiagnosed diabetes cases in the Mexican population and poor glycemic control reported by recent estimates, the burden of COVID-19 might be higher than expected in Mexico and pose a challenge for the Mexican health care system to give particular attention to this sector as the epidemic moves forward (31–33).

Diabetes mellitus is one of the main causes of morbidity, and it accounts for a large proportion of mortality risk in the Mexican population (4). Of relevance, Mexicans have increased risk of diabetes and diabetes-related obesity attributable to genetic variants associated with its Amerindian ancestry and an earlier age of onset independent of body mass index (BMI) (34, 35). Data on the incidence of early-onset type 2 diabetes in the Mexican population positions obesity and insulin resistance as significant risk factors, which increase metabolic risk and are also highly prevalent in younger patients (16, 36). These associations partly explain the increased risk of COVID-19 lethality in younger patients within our cohort despite the younger average age of the Mexican population, and these associations also pose early-onset diabetes mellitus as a significant risk factor for COVID-19 mortality and as an increased severity of infection in younger patients (5, 37).

In our work, we demonstrate that, compared to non-COVID-19 infections, obesity significantly modifies the risk of mortality attributable to COVID-19 infection. Obesity and, in particular, abdominal obesity, is one of Mexico's main public health problems; in recent years the socioeconomic burden of obesity as well as its impact on mortality have increased drastically, with the Ministry of Health declaring a state of epidemiological emergency (38). Evidence from different regions has supported the notion that obesity increases mortality risk and severity of COVID-19 infections, which holds particularly true for younger patients (2, 39). Obesity is characterized by low-grade inflammation, whereby mononuclear cells increase transcription of proinflammatory cytokines; obesity also interacts with insulin-resistant states, and metabolic syndrome traits are often comorbid in subjects with obesity to further promote inflammatory and a prothrombotic state, which might lead to deleterious responses to infectious pathogens (40, 41). Furthermore, obesity has been shown to lead to a decreased immune response to infectious pathogens, which in turn may also affect the

lung parenchyma, increasing the risk for inflammatory lung diseases of infectious causes, like influenza and SARS-CoV-2 (42–44). Similar inflammatory responses have been attributed to the low number of asthmatics with confirmed SARS-CoV-2 infection. Immune Th2 response observed in asthma may counter inflammation related to SARS-CoV-2 infection, as was previously reported for cases in Wuhan; however, increased proinflammatory processes in severe forms of COVID-19 likely outweigh the effect of asthma. Additionally, abdominal obesity reduces the compliance of lung, chest wall, and the entire respiratory system, resulting in impaired ventilation of the base of the lungs and reduced oxygen saturation of blood (45). Recently, Simonnet et al explored the high prevalence of obesity in patients with COVID-19, reporting that obesity is a risk factor for SARS-CoV-2 infection severity independent of age, diabetes, and hypertension. Notably, ACE2 expression in adipose tissue is higher than in the lung and its expression profile is not different in obese and nonobese subjects; however, obese subjects have more adipocytes, thus they have a greater number of ACE2-expressing cells and a higher likelihood of SARS-CoV-2 entry (2, 46). Our data shows that obesity is a specific risk factor for COVID-19-related outcomes and that it partly mediates the risk associated with diabetes mellitus. Public health efforts by the Mexican government in epidemiological surveillance have largely focused in identifying patients with the highest risk of complications; these findings could inform public health decisions and increase awareness about the role of obesity in modifying the risk of COVID-19 outcomes.

Our study had some strengths and limitations. First, we analyzed a large dataset, which included information on both confirmed positive and negative SARS-CoV-2 cases, and which provides a unique opportunity to investigate COVID-19-specific risk factors and develop a predictive model for COVID-19 mortality. Additionally, with the database being nationally representative, it allows for reasonable estimates on the impact of both diabetes and obesity despite the possibility of important regional differences in cardiometabolic risk, which might influence risk estimates. A potential limitation of this study is the use of data collected from a sentinel surveillance system model, which is skewed towards investigating high-risk cases or only those with specific risk factors. On one hand, this increases power to detect the effect of comorbidities and on the other hand might not be representative of milder cases of the disease; this is demonstrated in the risk of COVID-19 positivity, which is higher for high-risk cases. Updating daily estimates of COVID-19 cases are unlikely to



change the direction of the identified associations, though it might modify numeric estimates. The role of a risk gradient related to BMI and increasing degrees of obesity could not be explored with available data and remains an area to be explored in further studies. Implementation of our proposed model might be useful to allocate prompt responses to high-risk cases and improve stratification of disease severity.

In conclusion, we show that both diabetes and obesity increase the risk of SARS-CoV-2 infection in Mexico. In particular, diabetes increases the risk of COVID-19-related mortality and, specifically, increases mortality risk in early-onset cases. Obesity is a COVID-19-specific risk factor for mortality and for increased disease severity; obesity is also a partial mediator on the effect of diabetes in decreasing survival associated with COVID-19 infection. This mechanistic interpretation on the risk of comorbidities allowed for the development of a model with good performance to predict mortality in COVID-19 cases. Given the burden of obesity and diabetes in Mexico, COVID-19 lethality might be higher in younger cases. Special attention should be given to susceptible individuals and screening should be conducted for all symptomatic cases, with either obesity and/or diabetes in order to decrease the impact of both conditions on adverse COVID-19 outcomes in Mexico.

## Acknowledgments

J.P.B.L., A.V.V., N.E.A.V., A.M.S., and C.A.F.M. are enrolled at the Plan de Estudios Combinados en Medicina program of the Faculty of Medicine at Universidad Nacional Autónoma de México. J.P.B.L. and A.V.V. are supported by Consejo Nacional de Ciencia y Tecnología. The authors would like to acknowledge the invaluable work of all of Mexico's health care community in managing the COVID-19 epidemic, and its participation in the COVID-19 surveillance program has made this work a reality. We are thankful for your efforts.

**Author Contributions:** Research idea and study design by O.Y.B.C., J.P.B.L., C.A.A.S.; data acquisition by O.Y.B.C. and A.G.D.; data analysis/interpretation by O.Y.B.C., J.P.B.L., N.E.A.V., A.V.V., A.G.D., J.J.N., and C.A.A.S.; statistical analysis by O.Y.B.C. and N.E.A.V.; manuscript drafting by O.Y.B.C., N.E.A.V., A.V.V., J.P.B.L., A.M.S., C.A.F.M., and J.J.N.; supervision and mentorship by O.Y.B.C. and C.A.A.S. Each author contributed important intellectual content during the manuscript's drafting and revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

## Additional Information

**Correspondence and Reprint Requests:** Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatria. Anillo Perif. 2767, San Jerónimo Lídice, La

Magdalena Contreras, 10200, Mexico City, Mexico. E-mail: [oyaxbell@yahoo.com.mx](mailto:oyaxbell@yahoo.com.mx), Carlos A. Aguilar-Salinas. Unidad de Investigación de Enfermedades Metabólicas. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15. CP 14080; Tlalpan, Distrito Federal, México. E-mail: [caguilarsalinas@yahoo.com](mailto:caguilarsalinas@yahoo.com).

**Disclosure Summary:** The authors have nothing to disclose.

**Data Availability:** All data sources and the R code are available for reproducing their results at [https://github.com/oyaxbell/covid\\_diabetesmx](https://github.com/oyaxbell/covid_diabetesmx).

## References

1. Mexican Health Ministry. Información Internacional y Nacional sobre nuevo Coronavirus (COVID-2019) | Secretaría de Salud | Gobierno | gob.mx. <https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov>. Accessed May 19, 2020.
2. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation [Published online ahead of print April 9, 2020]. *Obesity (Silver Spring)*. 2020. doi:10.1002/oby.22831
3. Zhou F, Fan G, Liu Z, Cao B. SARS-CoV-2 shedding and infectivity - authors' reply. *Lancet*. 2020;395(10233):1340. doi:10.1016/S0140-6736(20)30869-2
4. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. *Nutr Rev*. 2017;75(suppl 1):4–12.
5. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020;323(16):1574–1581. doi:10.1001/jama.2020.5394
6. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis*. 2005;41(3):281–288.
7. Van Kerkhove MD, Vandemaële KAH, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLoS Med*. 2011;8:e1001053. doi:10.1371/journal.pmed.1001053
8. Luzzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. *Acta Diabetol*. 2020;57(6):759–764.
9. Jose RJ, Manuel A. Does COVID-19 disprove the obesity paradox in ARDS? *Obesity (Silver Spring)*. 2020;28(6):1007–1007. doi:10.1002/oby.22835
10. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. *Obesity (Silver Spring)*. 2020;28(6):1005–1005.
11. Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, et al. Overweight and obesity in Mexican vulnerable population. Results of Ensanut 100k. *Salud Publica Mex*. 2019;61(6):852–865.
12. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science*. 2020;368(6490):473–474.
13. Mexican Health Ministry. Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno | gob.mx. <https://www.gob.mx/salud/documentos/datos-abiertos-152127?idiom=es>. Accessed May 19, 2020.
14. Secretaria de Salud Subsecretaria de Prevencion y Promocion de la Salud Direccion General de Epidemiologia. *Lineamiento estandarizado para la Vigilancia Epidemiológica y por Laboratorio de la enfermedad respiratoria viral*. <https://www.gob.mx/salud/documentos/lineamiento-estandarizado-para-la-vigilancia-epidemiologica-y-por-laboratorio-de-la-enfermedad-respiratoria-viral>. Accessed on May 19, 2020.

15. Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. *Nat Rev Endocrinol.* 2020;16(6):321–331.
16. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, et al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. *Am J Med.* 2002;113(7):569–574.
17. Ng MC, Lee SC, Ko GT, et al. Familial early-onset type 2 diabetes in Chinese patients: obesity and genetics have more significant roles than autoimmunity. *Diabetes Care.* 2001;24(4):663–671.
18. Cho SH, Huang YT. Mediation analysis with causally ordered mediators using Cox proportional hazards model. *Stat Med.* 2019;38(9):1566–1581.
19. Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. Supplementary material: predicting mortality attributable to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. *medRxiv.* 2020. doi:10.1101/2020.04.20.20072223
20. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabet Med.* 2006;23(6):623–628.
21. Bello-Chavolla OY, Bahena-Lopez JP, Garcíadiago-Fosass P, et al. Bloodstream infection caused by *S. aureus* in patients with cancer: a 10-year longitudinal single-center study. *Support Care Cancer.* 2018;26(12):4057–4065.
22. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. *Acta Diabetol.* 2001;38(2):77–82.
23. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(13):382–386. doi:10.15585/mmwr.mm6913e2
24. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a Nationwide Analysis of China. *Eur Respir J.* 2020;55(6):2000562. doi:10.1183/13993003.00562-2020
25. Chen X, Hu W, Ling J, et al. Hypertension and diabetes delay the viral clearance in COVID-19 patients. *medRxiv.* 2020. doi:10.1101/2020.03.22.20040774
26. Rao S, Lau A, So HC. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of 2019-nCoV: a Mendelian Randomization analysis. *medRxiv.* 2020. doi:10.1101/2020.03.04.20031237
27. Fernandez C, Rysä J, Almgren P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. *J Intern Med.* 2018;284(4):377–387.
28. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science.* 2020;367(6483):1260–1263.
29. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. *Immunology.* 2015;144(2):171–185.
30. Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that increase morbidity [Published online ahead of print April 7, 2020]. *Metab Clin Exp.* 2020;108:154224. doi:10.1016/j.metabol.2020.154224
31. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr.* 2020;14(4):303–310. doi:10.1016/j.dsx.2020.04.004
32. Campos-Nonato I, Ramírez-Villalobos M, Flores-Coria A, Valdez A, Monterrubio-Flores E. Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican adults: ENSANUT-2016. *PLoS One.* 2020;15:e0230752. doi:10.1371/journal.pone.0230752
33. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. *Endocrine.* 2020;68(1):2–5.
34. Williams AL, Jacobs SBR, Moreno-Macías H, et al.; SIGMA Type 2 Diabetes Consortium. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. *Nature.* 2014;506(7486):97–101. doi:10.1038/nature12828
35. Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, et al. The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-size adipocytes. *Eur J Endocrinol.* 2019;180(2):99–107.
36. Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, et al. Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: the metabolic syndrome cohort. *BMC Endocr Disord.* 2019;19(1):41.
37. Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2 diabetes in a Mexican survey: results from the National Health and Nutrition Survey 2006. *Salud Publica Mex.* 2010;52(Suppl 1):S27–S35. doi:10.1590/s0036-36342010000700006
38. Nieto C, Tolentino-Mayo L, Monterrubio-Flores E, et al. Nutrition label use is related to chronic conditions among Mexicans: data from the Mexican National Health and Nutrition Survey 2016. *J Acad Nutr Diet.* 2020;120(5):804–814. doi:10.1016/j.jand.2019.07.016
39. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission [Published online ahead of print 2020 April 9]. *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa415
40. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. *Circulation.* 2004;110(12):1564–1571.
41. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation.* 2005;111(11):1448–1454.
42. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. *Int J Obes (Lond).* 2013;37(3):333–340. doi:10.1038/ijo.2012.62
43. Zhang X, Zheng J, Zhang L, et al. Systemic inflammation mediates the detrimental effects of obesity on asthma control. *Allergy Asthma Proc.* 2017. doi:10.2500/aap.2017.38.4096
44. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. *Int J Obes (Lond).* 2012;36(8):1072–1077.
45. Dixon AE, Peters U. The effect of obesity on lung function. *Expert Rev Respir Med.* 2018;12(9):755–767.
46. Jia X, Yin C, Lu S, et al. Two things about COVID-19 might need attention. 2020. doi:10.20944/preprints202002.0315.v1